Mefatinib as first-line treatment of patients with advanced non–small cell lung cancer harboring rare EGFR mutations.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Second Affiliated Hospital of Zhejiang University, Zhejiang University, Xiangya Hospital Central South University, West China Hospital of Sichuan University, Shanghai Pulmonary Hospital, Nanjing Drum Tower Hospital, Nanjing University, First Affiliated Hospital of Guangzhou Medical University, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Jiangsu Province Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281804160